Drug Type Small molecule drug |
Synonyms Basimglurant, NOE-101, RG-7090 + [1] |
Target |
Action antagonists |
Mechanism mGluR5 antagonists(Metabotropic glutamate receptor 5 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC18H15ClFN3O4S |
InChIKeyRPRPXJNEEIIWAL-UHFFFAOYSA-N |
CAS Registry1034442-21-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Basimglurant Sulfate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain | Phase 3 | United States | 11 Jan 2022 | |
Pain | Phase 3 | Denmark | 11 Jan 2022 | |
Pain | Phase 3 | Germany | 11 Jan 2022 | |
Pain | Phase 3 | Italy | 11 Jan 2022 | |
Pain | Phase 3 | Poland | 11 Jan 2022 | |
Pain | Phase 3 | Spain | 11 Jan 2022 | |
Pain | Phase 3 | Turkey | 11 Jan 2022 | |
Pain | Phase 3 | United Kingdom | 11 Jan 2022 | |
Trigeminal Neuralgia | Phase 3 | United States | 11 Jan 2022 | |
Trigeminal Neuralgia | Phase 3 | Denmark | 11 Jan 2022 |